BioCentury's websites will be down for upgrades starting at 9 p.m. PDT on Monday, August 26. We expect the downtime to last no more than 6 hours, and we apologize for any inconvenience.

12:00 AM
Jan 10, 2011
 |  BC Week In Review  |  Clinical News  |  Clinical Results

Aclidinium bromide: Phase III data

The double-blind, European and South African Phase III ATTAIN trial in 828 moderate to severe COPD patients showed that 200 and 400 ug twice-daily aclidinium met the primary endpoints of significantly improving morning trough FEV1 from baseline to week 12 vs. placebo (p<=0.0001) and to week 24 (p<0.0001). The week 12 endpoint was the study's primary endpoint for the U.S., and the week 24 endpoint was the primary endpoint for Europe.

Both the low and the high doses of aclidinium also...

Read the full 388 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >